iPSC– tag –
-
Protein Interactions Shed New Light on Autism Causes: Advancing Neurological Disease Understanding
Fierce Biotech USA Overview Research reports that complex protein-protein interactions offer new insights into the fundamental causes of autism spectrum disorder (ASD). This discovery is a critical step towards understanding the intricat... -
Cellistic Expands iPSC Therapy Manufacturing with New GMP Platforms for Immuno-Oncology and Regenerative Medicine
Cellistic Press Release (via PharmaTimes) Belgium Overview Cellistic has introduced three new GMP manufacturing platforms—Echo-T, Echo-Cardio, and Echo-Endothelial—significantly expanding its capabilities for iPSC-derived cell therapies.... -
AI-Guided 3D Bioreactors Revolutionize iPSC Manufacturing: Scaling Up and Cutting Costs for Accelerated Commercialization
Wiley Analytical Science USA Overview AI-guided 3D bioreactor technology is revolutionizing iPSC manufacturing, enabling reliable, efficient, and scalable production of pluripotent stem cells (PSCs). This innovative platform facilitates ... -
6th iPSC Drug Development Summit Focuses on Manufacturability, Regulatory Alignment, and Scalable Development Models
RegMedNet UK Overview The 6th iPSC Drug Development Summit is being held to actively discuss the clinical and commercial feasibility of iPSC therapies. The summit will focus on manufacturability, alignment with regulatory authorities, an... -
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Secures FDA Rare Pediatric Disease Designation, Advancing Clinical Trials for Cardiac & Rare Muscle Disorders
Facebook (IPS Heart) USA Overview IPS HEART announced that its iPSC-derived cell therapy, ISX9-CPC, received Rare Pediatric Disease Designation (RPDD) from the FDA. Targeting cardiac and rare muscle disorders, this designation positions ... -
USC Initiates Phase 1 REPLACE™ Clinical Trial for Parkinson’s with Autologous iPSC-Derived Dopaminergic Neurons (RNDP-001), Aiming to Restore Motor Function
Dr. Marie Laguna's Blog USA Overview Keck Medicine of USC commenced a Phase 1 REPLACE™ clinical trial in 2026 for Parkinson's disease, utilizing autologous iPSC-derived dopaminergic neural cells (RNDP-001). This innovative therapy aims t... -
Chinese Trial Reports 90% Heart Function Improvement in Phase 2 Heart Failure Patients Treated with iPSC-Derived Cardiomyocytes
South China Morning Post (SCMP) China Overview A Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China, using iPSC-derived cardiomyocytes for heart failure treatment, demonstrated significant improvement in heart funct... -
iPSC 20th Anniversary: Japan Leads with Conditional Approvals, Facing Challenges of Public Trust and Universal Access
Facebook (Science Vibes) USA Overview The 20th anniversary of iPSC discovery highlights significant progress in regenerative medicine, with Japan leading globally by granting the world's first conditional approvals for iPSC-derived thera... -
Commercial-Scale iPSC Cell Therapy Production Gains Traction with US Clinical Trial Progress and Master Cell Bank Establishment
The Medicine Maker UK Overview Manufacturing challenges for commercial-scale iPSC cell therapies are being overcome, with multiple iPSC clinical trials progressing in the U.S. for indications like Type 1 Diabetes, Parkinson's disease, an... -
REPROCELL Pioneers Integrated iPSC Manufacturing Platform, Accelerating US Phase III Clinical Programs with AI-Enhanced Gene Editing and GMP Compliance
REPROCELL Japan Overview REPROCELL has launched a comprehensive iPSC manufacturing platform designed to accelerate the clinical development of iPSC-derived therapeutics, notably supporting a US Phase III program. The platform integrates ...
